Program coordinator Sarah Solar is the nexus point for the UC Davis Institute for Psychedelics and Neurotherapeutics. They liaison between campuses, establish connections between faculty affiliates and the institute, track funding, and coordinate and manage communications, among a host of other tasks. Their fingers are on the institute’s pulse, ensuring its operational functionality.
UC Davis researchers have developed a new method that uses light to transform amino acids — the building blocks of proteins — into molecules that are similar in structure to psychedelics and mimic their interaction with the brain.
In a first-of-its-kind study appearing in Nature Communications, an interdisciplinary team from the university’s Institute for Psychedelics and Neurotherapeutics (IPN) dosed mouse mothers with psilocybin and found that the drug amplified anxiety and depressive-like symptoms associated with perinatal mood disorders — mental health conditions that can arise during or after pregnancy.
An interdisciplinary research collaboration between the California Lighting Technology Center, or CLTC, and the Center for Mind and Brain, or CMB, The Color Lab is part of an effort to implement human-centric lighting designs to optimize well-being.
University of California, Davis, researchers have developed a new, neuroplasticity-promoting drug closely related to LSD that harnesses the psychedelic’s therapeutic power with reduced hallucinogenic potential. The research highlights the new drug’s potential as a treatment option for conditions like schizophrenia, where psychedelics are not prescribed for safety reasons.
In a study appearing in Nature Chemistry, researchers at the University of California, Davis Institute for Psychedelics and Neurotherapeutics (IPN) report the successful total synthesis of ibogaine, ibogaine analogues and related compounds from pyridine — a relatively inexpensive and widely available chemical.
Delix Therapeutics recently announced that the first neuroplastogen drug based on UC Davis Institute for Psychedelics and Neurotherapeutics (IPN) research will be tested in patients with major depressive disorder.
New research shows that the anti-anxiety and hallucinogenic-like effects of a psychedelic drug work through different neural circuits. The study, in a mouse model, shows that it could be possible to separate treatment from hallucinations when developing new drugs based on psychedelics.
A new study shows how children’s and adolescents’ memories of the COVID lockdowns of 2020 and 2021 changed over time and related to their mental health.
